HANDOK Inc. (KRX:002390)
South Korea · Delayed Price · Currency is KRW 11,660
+70 (0.60%)
At close: Nov 26, 2025
HANDOK Revenue
HANDOK had revenue of 144.68B KRW in the quarter ending September 30, 2025, with 12.12% growth. This brings the company's revenue in the last twelve months to 516.37B, up 0.72% year-over-year. In the year 2024, HANDOK had annual revenue of 507.36B, down -2.94%.
Revenue (ttm)
516.37B
Revenue Growth
+0.72%
P/S Ratio
0.29
Revenue / Employee
549.33M
Employees
940
Market Cap
151.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 507.36B | -15.38B | -2.94% |
| Dec 31, 2023 | 522.74B | -21.02B | -3.87% |
| Dec 31, 2022 | 543.76B | 26.12B | 5.05% |
| Dec 31, 2021 | 517.64B | 14.03B | 2.79% |
| Dec 31, 2020 | 503.61B | 30.61B | 6.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |